Harvoni’s growth spurt despite Hep C market downturn

By Nho, Byung Chul | translator Alice Kang

21.07.20 06:00:40

가나다라 0

Maviret sales show external decline with ₩14.4billion·₩57.3 billion·₩46.9 billion in sales in 2018·2019·2020

Harvoni makes ₩6.8 billion·₩15.7billion·₩18.4 billion in sales...the only product to see a surplus in its market

Zepatier·Sovaldi·Daklinza·Sunvepra... ₩2.6 billion·₩0.7 billion·₩0.6 billion·₩17 million

With the domestic hepatitis C treatment market externally contracting from ₩120 billion to ₩68 billion in three years, the rapid strides of growth made by Harvoni in the market is drawing attention.

On the 20th, Dailypharm analyzed the hepatitis C treatment market based on IQVIA data. The overall sales in the Hep C market amounted to ₩121.2 billion·₩89.9 billion·₩85.2 billion·₩68.8 billion in the years 2017·2018·2019·2020.

The leading product in the market was AbbVie’s Maviret, which recorded ₩47.9 billion in sales last year. Maviret still is the sole lead product that accounts for 70% of the market, however, its sales fell ₩10.4 bil

Nho, Byung Chul(sasiman@dailypharm.com)

If you want to see the full article, please JOIN US (click)